International Journal of Pediatrics Research

Objective To explore the effect of combined treatment of azithromycin and montelukast sodium in children with Mycoplasma pneumoniae pneumonia. Methods From April 2021 to August 2022, a total of 60 children were selected from the clinical department of pediatrics and randomly divided into the control group (conventional azithromycin antibacterial treatment) and the study group (azithromycin + montelukast sodium), with 30 children in each group, and the comprehensive efficacy was compared. Results The levels of CRP, IgG, IgA and IgM in the study group were lower than those in the control group (P < 0.05). The remission time of cough, fever, pulmonary rales and other symptoms and hospital stay in the study group were shorter than those in the control group (P < 0.05). Before treatment, there was little difference in pulmonary function indexes between the two groups (p > 0.05). After treatment, the pulmonary function indexes of the two groups were improved. The levels of FEVI, PEF and FVC in the study group were significantly higher than those in the control group (P < 0.05). Conclusion Montelukast sodium on the basis of conventional antimicrobial treatment for Mycoplasma pneumoniae pneumonia in children can effectively strengthen the synergistic effect of drugs, improve the pulmonary function of children, and improve the body immunity.

Azithromycin; Montelukast sodium; Mycoplasma pneumonia in children; Immune index; Lung function